Ketorolac in Upper Extremity Tendinopathy and Arthropathy
Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and keto
| Condition(s) | Osteoarthritis, Tendinopathy, Arthropathy |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the duration of symptomatic relief exist for arthropathy and tendinopathy of these joints. The goal of this study is to evaluate the efficacy of ketorolac and triamcinolone injections for common shoulder, elbow, wrist, and hand tendinopathy or arthropathy. Participants will be blinded to the treatment receiv |
| Who can participate | Inclusion Criteria: * Age 18 or older, * symptomatic tendinopathy or arthropathy of the shoulder, elbow, hand, or wrist who have not undergone prior surgical treatment for their condition. * Diagnoses may include trigger finger, De Quervain's tenosynovitis, radiocarpal osteoarthritis, first carpometacarpal (CMC) joint osteoarthritis, metacarpophalangeal joint osteoarthritis, or proximal interphalangeal joint osteoarthritis. Exclusion Criteria: * Patients under the age of 18, * Patients who have undergone prior triamcinolone or ketorolac injections within the past 6 months, * Patients who have undergone prior surgical treatment for their hand condition, * Patients with allergy or contraindication to triamcinolone or ketorolac injection, * Patients with an active infection at the treatment s |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Emory University |
| Locations | Atlanta, Georgia, United States; Atlanta, Georgia, United States; Atlanta, Georgia, United States; Atlanta, Georgia, United States |
| Start date | 2023-01-31 |
| NCT ID | NCT05292339 |
| Official listing | https://clinicaltrials.gov/study/NCT05292339 |